Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.15 million
Profitability
Miscellaneous
Employees148
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The firm had revenue of $3.76 million for the quarter, compared to the consensus estimate of $3.56 million. Cronos Group had a negative net margin of 45.72% and a negative return on equity of 3.22%. The business's revenue was up 187.0% compared to the same quarter last year. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
4 brokerages have issued twelve-month price objectives for Cronos Group's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Cronos Group's stock price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 39.6%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
News stories about CRON stock have been trending positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cronos Group earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Tilray (TLRY), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF) and Tauriga Sciences (TAUG).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 32)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.04%), USA Mutuals Advisors Inc. (0.04%) and First Command Bank (0.00%).
Which major investors are buying Cronos Group stock?
CRON stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, USA Mutuals Advisors Inc. and First Command Bank.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $14.90.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.38 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
